ESR1 and breast carcinoma: Firstly, although RS was initially validated for use in patients being treated for ER+/HER2− breast cancer with axillary lymph node-negative disease, the paradigm has evolved in recent years to highlight the utility of the RS in cases of 1–3 positive lymph nodes in the axilla [58].